The Food and Drug Administration on Thursday approved Amgen’s new migraine drug, Aimovig, which is used to prevent migraine headaches in adults.
According to a CNBC article, the self-injected drug carries a list price of $6,900 per year ($575 per month).
Amgen spokeswoman Kristen Davis said any discounts and rebates would hinge on payer negotiations.
The new drug is the first entry in a new class of treatments aimed at preventing migraines by targeting calcitonin gene-related peptide (CGRP). Teva Pharmaceutical Industries and Eli Lilly are reportedly working to create similar therapies.